Wang H
Institute of psychological medicine, Nanjing Command, PLA, Changzhou, Jiangsu province.
Zhonghua Shen Jing Jing Shen Ke Za Zhi. 1992 Feb;25(1):6-8, 60.
Blood CuZn superoxide dismutase (CuZn-SOD) changes during neuroleptic drugs treatment were measured by means of double-antibody immunoradiometric assay, in 121 schizophrenics (77 cases with Type I and 44 cases with Type II), and 128 normal subjects as control group. The results revealed: (1) before treatment, the overall blood content of CuZn-SOD in patient group showed higher significantly than that of control group (t = 12.34, P less than 0.001); (2) the content of CuZn-SOD in Type I schizophrenics was higher than that of Type II (t = 13.93, P less than 0.001); (3) after treatment, the CuZn-SOD content decreased obviously in Type I (t = 7.715, P less than 0.001), while no significant change in Type II was encountered (t = 0.541, P less than 0.05). The pathophysiological mechanisms of dopamine-Oxygen free radicals relating to the Type I and Type II schizophrenics was discussed briefly.
采用双抗体免疫放射分析法测定了121例精神分裂症患者（Ⅰ型77例，Ⅱ型44例）及128例正常对照者在使用抗精神病药物治疗期间血铜锌超氧化物歧化酶（CuZn-SOD）的变化。结果显示：（1）治疗前，患者组血CuZn-SOD总体含量显著高于对照组（t = 12.34，P＜0.001）；（2）Ⅰ型精神分裂症患者CuZn-SOD含量高于Ⅱ型（t = 13.93，P＜0.001）；（3）治疗后，Ⅰ型患者CuZn-SOD含量明显下降（t = 7.715，P＜0.001），而Ⅱ型患者未出现显著变化（t = 0.541，P＞0.05）。并简要讨论了多巴胺-氧自由基与Ⅰ型和Ⅱ型精神分裂症相关的病理生理机制。
